Market Overview

UPDATE: Jefferies Downgrades GlaxoSmithKline to Hold on Margin Expansion Visibility

Share:
Related GSK
GlaxoSmithKline And Innoviva Plan To File A NDA For Triple Combination Therapy
GlaxoSmithKline, Innoviva Offer Regulatory Update on US Filing Plans for Closed Triple Combo Therapy FF/UMEc/VI for Patients with COPD
Teva launches generic version of Glaxo's migraine med Imitrex in U.S. (Seeking Alpha)

Jefferies cut its rating on GlaxoSmithKline (NYSE: GSK) from Buy to Hold on reduced visibility to the company's margin expansion.

Jefferies commented, "Whilst we still see double digit CORE EPS growth for GlaxoSmithKline from 2013E-17E, visibility on margin expansion has been obscured by over-exposure to price pressure and transfer pricing in Europe. The shares have recovered well from their lows since the Q2'12 results and we take this opportunity to cut our rating to Hold from Buy given the limited upside."

GlaxoSmithKline closed at $46.84 on Friday.

Latest Ratings for GSK

DateFirmActionFromTo
Feb 2016Cantor FitzgeraldInitiates Coverage onHold
Jan 2016Bryan GarnierUpgradesNeutralBuy
Oct 2015Credit SuisseUpgradesUnderperformNeutral

View More Analyst Ratings for GSK
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (GSK)

View Comments and Join the Discussion!